Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity
Molecules · 2023
DOI: 10.3390/molecules28186643 ↗At a glance
Journal article in Molecules, 2023. Written by Cintia A Menendez and 13 co-authors. Institution: Pritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA. Major MEDLINE topics: Piperidines, Benzamides, Pyridines. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIGMS NIH HHS, Department of Energy, Office of Science.
Abstract (original language)
Recently, a high-throughput screen of 1900 clinically used drugs identified masitinib, an orally bioavailable tyrosine kinase inhibitor, as a potential treatment for COVID-19. Masitinib acts as a broad-spectrum inhibitor for human coronaviruses, including SARS-CoV-2 and several of its variants. In this work, we rely on atomistic molecular dynamics simulations with advanced sampling methods to develop a deeper understanding of masitinib’s mechanism of Mpro inhibition. To improve the inhibitory efficiency and to increase the ligand selectivity for the viral target, we determined the minimal portion of the molecule (fragment) that is responsible for most of the interactions that arise within the masitinib-Mpro complex. We found that masitinib forms highly stable and specific H-bond interactions with Mpro through its pyridine and aminothiazole rings. Importantly, the interaction with His163 is a key anchoring point of the inhibitor, and its perturbation leads to ligand unbinding within nanoseconds. Based on these observations, a small library of rationally designed masitinib derivatives (M1–M5) was proposed. Our results show increased inhibitory efficiency and highly reduced cytotoxicity for the M3 and M4 derivatives compared to masitinib.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Pritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
- Department of Chemistry, University of Chicago, 5735 South Ellis Avenue, Chicago, IL 60637, USA.
- Argonne National Laboratory, 9700 South Cass Avenue, Lemont, IL 60439, USA.
ORCID profiles: Gustavo R Perez-Lemus, Adam M Weiss, Emma Kenna, Fabian Byléhn
Funding
- NIGMS NIH HHS
- Department of Energy
- Office of Science
- Basic Energy Sciences
- Division of Materials Science and Engineering
- NSF
- NIH Chemistry-Biology Interface training
Cite
APA
Menendez, C. A., Mohamed, A., Perez-Lemus, G. R., Weiss, A. M., Rawe, B. W., Liu, G., Crolais, A. E., Kenna, E., Byléhn, F., Alvarado, W., Mendels, D., Rowan, S. J., Tay, S., & de Pablo, J. J. (2023). Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. https://doi.org/10.3390/molecules28186643
Vancouver
Menendez CA, Mohamed A, Perez-Lemus GR, Weiss AM, Rawe BW, Liu G, et al. Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023. doi:10.3390/molecules28186643
BibTeX
@article{Menendez2023,
author = {Menendez, Cintia A and Mohamed, Adil and Perez-Lemus, Gustavo R and Weiss, Adam M and Rawe, Benjamin W and Liu, Guancen and Crolais, Alex E and Kenna, Emma and Byléhn, Fabian and Alvarado, Walter and Mendels, Dan and Rowan, Stuart J and Tay, Savaş and de Pablo, Juan J},
title = {Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28186643}
}
EUVIMED